Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET fusion |
| Therapy | Zeteletinib |
| Indication/Tumor Type | pancreatic cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET fusion | pancreatic cancer | predicted - sensitive | Zeteletinib | Case Reports/Case Series | Actionable | In a Phase I trial, Zeteletinib (DS-5010) treatment resulted in an objective response rate (ORR) of 33% (18/54) in patients with RET-altered advanced solid tumors including an ORR of 33% (10/30) in non-small cell lung cancer patients harboring a RET fusion, an ORR of 44% (7/16) in patients with medullary thyroid cancer harboring RET mutations, and a partial response in a pancreatic cancer patient (J Clin Oncol 2021 39: 15_suppl, 3008; NCT03780517). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results | Full reference... |